As a corollary, the currently ongoing COLUMBUS-AD will assess a combination of encorafinib (BRAF inhibitor) and binimetinib (MEK inhibitor) in stage IIB/IIC melanoma [58]. This evidence concerns the gene MAP2K7 and melanoma.